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CASE REPORT
A 43-year-old never-smoking woman presented with 
a palpable mass in the left breast. Chest radiography and 
computed tomography revealed a 5-cm solitary tumor in 
the left upper lung field (Fig. 1A, B) and multiple medi-
astinal lymph node enlargements in addition to the breast 
tumor.  Contrast-enhanced brain magnetic resonance imag-
ing revealed multiple, asymptomatic metastases in the brain 
(Fig. 1C) and a skin metastasis in the scalp. Bone metasta-
sis in the pelvis and hepatic metastasis were also observed. 
The resected breast sections revealed malignant neoplasia 
organized into either solid nests or trabeculae of tumor cells 
with necrotic foci and rosette-like structures (Fig. 2A). Tumor 
cells showed moderately abundant cytoplasm, pleomorphic 
and vesicular nuclei, and mitosis (up to 20 mitoses/2 mm2). 
Immunohistochemical analysis showed that the tumor cells 
were diffusely and strongly positive for cytokeratin (CK) 7, 
pan-CK, and neuroendocrine markers (chromogranin, synap-
tophysin [Fig. 2B], and CD56) and negative for thyroid tran-
scription factor-1, estrogen receptor, progesterone receptor, 
CK5/6, and CK20. Breast tumor specimen analysis before 
treatment indicated a malignant neoplasm with neuroendo-
crine structure that was positive for neuroendocrine markers, 
leading to a diagnosis of a large-cell neuroendocrine carci-
noma (LCNEC) with suspected metastasis. Transbronchial 
biopsy of the lung tumor before treatment showed pathologi-
cal and immunohistochemical findings similar to the findings 
for breast tumor. Tumor cells from the lung, breast, and skin 
were diffusely and strongly positive for anaplastic lymphoma 
kinase (ALK) by immunohistochemistry using rabbit mono-
clonal antibody (D5F3; Cell Signaling Technology, Danvers, 
MA) (Fig. 2C). Fluorescence in situ hybridization analysis 
with break-apart probes for the ALK gene indicated the pres-
ence of an ALK rearrangement in the breast (Fig. 2D) and lung 
tumors and skin metastasis. Multiplex reverse transcriptase–
polymerase chain reaction revealed amplification of echino-
derm microtubule–associated protein-like 4  (EML4)-ALK 
variant 2 (E20; A20) in the breast tumor. Clinically, the tumors 
were diagnosed as primary lung carcinoma with metastases, 
including metastasis to the breast. The patient was treated with 
crizotinib, the first clinically available ALK tyrosine kinase 
inhibitor, and the lung tumors remained stable with treatment. 
Six weeks later, enhanced brain magnetic resonance imaging 
revealed marked increase in the size of the right cerebellar 
and left temporal lesions (Fig. 1D) and progression of the skin 
metastasis, indicating both resistance of the tumors to crizo-
tinib and progressive disease.
DISCUSSION
The case presented here is thought to be the first report 
of an LCNEC harboring an EML4–ALK rearrangement that 
also showed resistance to the ALK inhibitor crizotinib. In a 
subset of non–small-cell lung carcinoma, rearrangement 
of the EML4 and ALK genes creates the oncogenic fusion 
gene EML4–ALK, which encodes a chimeric protein with 
constitutive kinase activity that is most commonly seen in 
adenocarcinoma1–3 and has been reported in two previous 
cases of small-cell carcinoma.4,5 However, neither ALK rear-
rangement nor amplification have been previously observed 
in LCNEC.6 Wong et al.2 reported that two of 13 cases har-
boring EML4–ALK rearrangements had unusual histological 
features representing squamous and glandular components. 
Therefore, some combined carcinomas comprising adenocar-
cinoma and nonadenocarcinoma components may show ALK 
arrangement. In this case, the primary lung tumor may have 
been a combination of LCNEC and adenocarcinoma. Clinical 
trials report that the ALK inhibitor crizotinib is highly effec-
tive for patients with the ALK rearrangement.7 However, as 
the tumor in this case was resistant to crizotinib, ALK rear-
rangement may not be of practical importance in LCNEC, and 
neuroendocrine tumors harboring this rearrangement may be 
less responsive to ALK inhibitors.
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FIGURE 2.  Histopathological findings 
of the breast. A, Low-power image of a 
hematoxylin and eosin–stained section 
from the breast tumor showing cells 
organized in solid nests or forming 
trabeculae with foci of necrosis and 
rosette-like structures; (B) immunohis-
tochemical analysis of the breast tumor 
showing strong diffuse synaptophysin 
positivity; (C) immunohistochemical 
analysis showing strong diffuse ALK 
positivity; (D) fluorescence in situ 
hybridization analysis of the ALK locus 
using a break-apart probe strategy. 
Approximately 58% of breast tumor 
cells showed rearrangement at the ALK 
locus, as demonstrated by split red/
green signals (arrows). ALK, anaplastic 
lymphoma kinase.
FIGURE 1.  Imaging findings. A, Chest 
radiograph on admission showing a 
mass in the left upper field; (B) chest 
computed tomography scan on admis-
sion showing a lung mass in the left 
upper lobe; (C) enhanced brain MRI 
scan on admission showing metas-
tasis to the right cerebellar region; 
(D) subsequent enhanced brain MRI 
revealing an increase in the size of the 
right cerebellar lesion. MRI, magnetic 
resonance imaging.
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